Clovis Oncology, Inc. (NASDAQ:CLVS) tinted loss of -0.53% (-0.13 points) to US$24.24. The volume of 1.36 Million shares climbed down over an trading activity of 2.51 Million shares. EPS ratio determined by looking at last 12 month figures is -2.97. Over the same time span, the stock marked US$65.24 as its best level and the lowest price reached was US$11.5. The corporation has a market cap of US$1.28 Billion.
Clovis Oncology, Inc. (NASDAQ:CLVS)’s earnings per share has been growing at a -5.7 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -105.1 percent while most common profitability ratio return on investment (ROI) was -27.3 percent. The company’s institutional ownership is monitored at 0 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 79.8 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 3 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 3 think it is Hold. Recently, analysts have updated the overall rating to 2. 6 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Ensco plc (NYSE:ESV) is worth US$2.02 Billion and has recently fallen -2.52% to US$4.65. The latest exchange of 9.94 Million shares is above its average trading activity of 14.33 Million shares. The day began at US$4.74 but the price moved to US$4.61 at one point during the trading and finally capitulating to a session high of US$4.82. The stock tapped a 52-week high of US$9.51 while the mean 12-month price target for the shares is US$6.9.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 0.24, and a price to sales ratio of 1.15. For the past 5 years, the company’s revenue has grown -12.7%, while the company’s earnings per share has grown -17%. With an institutional ownership near 89.8%, it carries an earnings per share ratio of -1.46.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 7 brokerage firms polled by Factset Research. At present, 9 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 2 analysts call it Underweight, while 9 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.22.